Related Experiment Video
Updated: May 3, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions
A Pacelli1, J Greenman, C Cawthorne
1School of Biological, Biomedical and Environmental Sciences, University of Hull, Hull, HU6 7RX, UK.
None:
The role of cyclooxygenase (COX)-2 as a driving force in early tumourigenesis and the current interest in the combination of COX-2 inhibitors with standard therapy in clinical trials creates an urgent need to establish clinically relevant diagnostic tests for COX-2 expression. Molecular imaging using small-molecule probes radiolabelled for both positron emission tomography (PET) and single photon emission computed tomography (SPECT) offers the potential to meet this need, providing a minimally invasive readout for the whole disease burden. This review summarises current approaches to the radiolabelling of small-molecule COX-2 inhibitors and their analogues for PET and SPECT imaging, and gives an overview of their biological evaluation and likely success of clinical application.
More Related Videos
Related Concept Videos
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Targeted Cancer Therapies
There are several types of targeted therapies against...

